Subscribe to magazine
Subscribe to newsletters
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Radiation Dose management
Intravascular imaging systems
Peripheral Artery Disease
Leads, implantable devices
Implantable cardioverter defibrillators (ICD)
Cardiac resynchronization therapy devices (CRT)
Heart Valve Technology
Left atrial appendage (LAA) occluders
Structural heart occluders/closure devices
Clinical decision support
March 10, 2010
Drug Attacks Cholesterol In Two Ways
Vytorin is a medicine used to lower levels of total cholesterol, LDL (bad) cholesterol, and fatty substances called...
March 10, 2010
Drug Offers Different Way to Fight Cholesterol
Unlike the most common cholesterol-lowering medicines, statins, that work mainly in the liver, a new drug attempts to...
December 22, 2009
Drug Company Files Cholesterol Medication Patent Challenge
December 22, 2009 – A drug manufacturer recently filed paperwork with the FDA to produce a generic version of the...
August 06, 2009
Merck, Schering-Plough Resolve Civil Class-Action Lawsuits Related to VYTORIN, ZETIA
August 6, 2009 – Merck & Co. Schering-Plough Corp. and the companies' cholesterol joint venture, Merck/Schering-...
March 09, 2009
ZETIA, VYTORIN Makers Merck, Schering-Plough Merge in $41.1 Billion Deal
March 9, 2009 – Merck & Co. Inc. and Schering-Plough Corp. today said their Boards of Directors unanimously...
July 22, 2008
Cholesterol-Lowering Drugs Decrease Coronary Artery Disease, But Not Aortic Valve Disease
July 23, 2008 – A recent study found intensive LDL-cholesterol lowering with the combination of the drugs simvastatin
April 18, 2007
Schering-Plough Plans Phase III of Antiplatelet Clinical Trials
April 19, 2007 — Schering-Plough Corp.
Scranton Gillette Communications
. All Rights Reserved.
Terms and Conditions